News & Perspective

Nov 27, 2001

Nov 27, 2001

CDC smallpox plan favors focused vaccination program over mass campaign

(CIDRAP News) – If smallpox reappears in the United States, health authorities will strive to trace and vaccinate everyone who has had contact with infected or exposed persons but probably will not mount any mass vaccination campaigns, according to a draft plan released Monday by the Centers for Disease Control and Prevention (CDC).

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Dec 21, 2001

Dec 21, 2001

Congress approves $2.5 billion for bioterrorism preparedness

(CIDRAP News) – In a flurry of pre-adjournment activity yesterday, Congress appropriated about $2.5 billion for bioterrorism preparedness, including $1 billion for state and local efforts, according to an aide to Sen. Bill Frist, R-Tenn.

Jan 18, 2002

Jan 18, 2002

Military concerned over possible link between anthrax vaccine and birth defects

(CIDRAP News) – A preliminary study linking anthrax vaccinations in pregnant women with an increased risk of birth defects in their babies has prompted the US military to step up efforts to prevent immunization of pregnant women.

Feb 14, 2002

Feb 14, 2002

CDC says it's too soon to tell if anthrax vaccine increases risk of birth defects

(CIDRAP News) – The Centers for Disease Control and Prevention (CDC) says it will take several months to determine if women in the US military who received anthrax vaccine in the first trimester of pregnancy had a greater risk of bearing children with birth defects.

Mar 07, 2002

Mar 07, 2002

IOM says anthrax vaccine is safe and effective but needs improvement

(CIDRAP News) – A committee of the Institute of Medicine (IOM) has concluded after 17 months of study that the existing anthrax vaccine is effective and "acceptably safe," but a new vaccine that requires fewer doses and that causes fewer reactions is needed.

Jul 01, 2002

Jul 01, 2002

Pentagon will turn over part of anthrax vaccine supply for civilian use

July 1, 2002 (CIDRAP News) – About half of the nation's supply of anthrax vaccine—previously dedicated almost entirely to military use—will henceforward be set aside for civilian use in the event of another anthrax attack, federal defense and health officials announced Jun 28.

Aug 27, 2002

Aug 27, 2002

Bacteriophage enzyme selectively detects and kills anthrax, researchers say

(CIDRAP News) – Researchers at Rockefeller University report that they have isolated an enzyme from a bacteriophage that shows promise as a tool to quickly detect and kill Bacillus anthracis, the anthrax bacterium.

Nov 22, 2002

Nov 22, 2002

Homeland Security law leaves HHS in control of bioterrorism preparedness

(CIDRAP News) – In passing a bill to create a Department of Homeland Security (DHS) this week, Congress left the Department of Health and Human Services (HHS) in charge of most bioterrorism preparedness and civilian biodefense research programs—to the relief of medical research and public health groups.

Dec 05, 2002

Dec 05, 2002

With smallpox vaccination campaign likely, CDC seeks to expand VIG supply

(CIDRAP News) – As the likelihood of a large-scale smallpox vaccination program grows, the Centers for Disease Control and Prevention (CDC) is seeking to expand the government's limited supply of vaccinia immune globulin (VIG), the mainstay of treatment for severe reactions to the vaccine.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»